Filter by: patients
Home > Community Treatment Reports and Side Effects > MS Phase 3 Daclizumab Study DECIDE Treatment Report
What is MS Phase 3 Daclizumab Study DECIDE?

NCT01064401 is a double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting MS. Other study names are 205MS301, 2009-012500-11.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 1 1 Efficacy_cant_tell

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Commonly reported side effects, conditions, and hospitalizations associated with MS Phase 3 Daclizumab Study DECIDE

Asthma 1

Reported Stop Reasons

Why Patients Stopped Using MS Phase 3 Daclizumab Study DECIDE (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 1   Other: 100%

See all 1 patient who’ve stopped using MS Phase 3 Daclizumab Study DECIDE

Reported Duration See details about how long patients take this treatment ▼

Stopped Using MS Phase 3 Daclizumab Study DECIDE

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of MS Phase 3 Daclizumab Study DECIDE

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of MS Phase 3 Daclizumab Study DECIDE

Very
 1 100%
Somewhat
 0 0%
A little
 0 0%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of MS Phase 3 Daclizumab Study DECIDE

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 27, 2012.